|1.||Cao, Gabriel: 2 articles (01/2015 - 08/2012)|
|2.||Toblli, Jorge E: 2 articles (01/2015 - 08/2012)|
|3.||Angerosa, Margarita: 2 articles (01/2015 - 08/2012)|
|4.||Soule, Steven G: 2 articles (07/2009 - 03/2009)|
|5.||Schouten, Belinda J: 2 articles (07/2009 - 03/2009)|
|6.||Hunt, Penelope J: 2 articles (07/2009 - 03/2009)|
|7.||Mehta, B C: 2 articles (04/2003 - 11/2001)|
|8.||Aycicek, Ali: 1 article (01/2014)|
|9.||Oymak, Yesim: 1 article (01/2014)|
|10.||Koc, Ahmet: 1 article (01/2014)|
|1.||Iron-Deficiency Anemia (Anemia, Iron Deficiency)
01/01/2007 - "The efficacy of iron polymaltose complex (IPC) in the treatment of iron deficiency anemia (IDA) during pregnancy has not been well established, and the evidence is inconclusive. "
08/01/2012 - "The originator iron polymaltose complex (Maltofer®, IPC, Vifor International, St. Gallen, Switzerland) has been used for over 30 years to treat iron deficiency anemia. "
02/01/2012 - "Effects of iron deficiency anemia and its treatment with iron polymaltose complex in pregnant rats, their fetuses and placentas: oxidative stress markers and pregnancy outcome."
06/01/2007 - "Ineffectiveness of oral iron hydroxide polymaltose in iron-deficiency anemia."
09/01/2003 - "Ineffectiveness of iron polymaltose in treatment of iron deficiency anemia."
|2.||Anaphylaxis (Anaphylactic Shock)
11/01/2010 - "Intravenous iron polymaltose infusions are commonly used in the hospital setting with low rates of reported adverse reactions (including low rates of anaphylaxis and anaphylactoid reactions). "
10/01/2006 - "An audit of the in-hospital safety and tolerability of 401 infusions of iron polymaltose in 386 patients has shown no cases of anaphylaxis or other cardiorespiratory compromise. "
02/09/2005 - "An anaphylactic reaction after intravenous Fe injection (Ferrum Hausmann) occurred in an 84-year-old female patient on treatment for iron deficiency anemia. "
|3.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
11/01/2005 - "To compare the effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage and clinical disease activity in patients with inflammatory bowel disease. "
11/01/2005 - "Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease."
01/01/2015 - "Iron polymaltose complex had negligible effects on colonic tissue erosion, local or systemic oxidative stress, and local or systemic inflammation, even at high therapeutic doses, and may thus represent a valuable oral treatment of iron deficiency in inflammatory bowel disease."
11/01/2005 - "Forty-one patients with inflammatory bowel disease and iron deficiency were randomized to treatment with ferrous sulphate 100 mg twice a day or iron-polymaltose complex 200 mg once a day for 14 days. "
03/01/2009 - "Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia."
10/01/2013 - "This group includes various disorders such as X-linked, autosomal dominant and autosomal recessive hypophosphatemic rickets/osteomalacia, tumor-induced osteomalacia, and rickets/osteomalacia caused by the administration of iron polymaltose or saccharated ferric oxide. "
06/01/1998 - "One-hundred children, 48 males and 52 females, mean age +/- SD 39.9 +/- 28.2 months (range 12 to 113) with sideropenia or sideropenic anemia were randomly divided into 2 groups of 50 patients each (groups A and B) and were treated with iron protein succinylate (group A) or iron hydroxide polymaltose complex (group B). "
11/01/1963 - "[EFFECTIVENESS OF THE NON-ORAL IRON DRUG, IRON-POLYMALTOSE, IN ANEMIA]."
|5.||iron protein succinylate
|7.||gluconic acid (gluconate)
|8.||sodium sulfate (sodium bisulfate)
|9.||ferrous gluconate (Dextriferron)
|10.||saccharated ferric oxide